HB1360 requires coverage for FDA-approved treatments and diagnostic testing intended to slow the progression of Alzheimer’s disease and related dementias. The bill adds a new Section 356z.80 to the Illinois Insurance Code requiring group and individual accident and health insurance policies, as well as managed care plans, to cover medically necessary diagnostic testing and FDA-approved treatments or medications prescribed by a physician, so long as they are used in accordance with the FDA label. The bill also specifies that this coverage may not be subject to step therapy. For managed care plans under contract with the Department of Healthcare and Family Services, the new insurance-code coverage mandate does not apply.
The bill also amends several public-employee and local-government health coverage statutes to align them with the new Alzheimer’s coverage requirement. It updates the State Employees Group Insurance Act, the Counties Code, the Illinois Municipal Code, the School Code, the Health Maintenance Organization Act, the Limited Health Service Organization Act, and the Voluntary Health Services Plans Act so that the affected plans and entities are subject to the new coverage rules and related insurance-code provisions. In the State Employees Group Insurance Program, the Alzheimer’s coverage begins July 1, 2025, and that section is repealed July 1, 2027; for private and other applicable plans, the new insurance-code mandate applies to policies issued, amended, delivered, or renewed on or after January 1, 2027.
The bill’s impact on state law is primarily to expand mandated health benefits across a broad set of insurance arrangements in Illinois, including state employee coverage and many regulated health plans. It also reinforces enforcement authority by the Department of Insurance and, for certain public-employee coverage provisions, the Department of Central Management Services. In practical terms, insurers, HMOs, and self-insured public employers covered by the referenced statutes would need to ensure coverage for qualifying Alzheimer’s-related diagnostic testing and medications, and they would be prohibited from using step therapy to delay access to those treatments.
Overall sentiment appears favorable and supportive of expanded access to Alzheimer’s treatment, based on the bill’s subject matter and the absence of recorded opposition, committee debate, or recorded votes in the provided materials. The bill title and structure suggest a health-care access measure aimed at patients and families affected by Alzheimer’s disease and related dementias. No committee testimony or voting history is provided, so there is no documented public controversy in the supplied record.
The main potential points of contention, based on the text alone, are cost and coverage administration. Insurers and public employers could be concerned about premium impacts, utilization management limits, and the expense of newer FDA-approved Alzheimer’s therapies and associated diagnostic testing. Another possible issue is the bill’s exclusion of certain managed care plans under contract with the Department of Healthcare and Family Services, which creates a narrower application for some publicly administered coverage arrangements. The step-therapy prohibition may also be a point of concern for payers that rely on prior authorization or treatment sequencing to manage costs.
HB1360 amends the Illinois Insurance Code and multiple public-employee and local-government health coverage statutes to require coverage of medically necessary diagnostic testing and FDA-approved treatments or medications that slow the progression of Alzheimer’s disease or related dementias. It applies this mandate to group and individual accident and health policies, managed care plans, HMOs, limited health service organizations, voluntary health services plans, and certain self-insured public employers, while excluding managed care plans under contract with the Department of Healthcare and Family Services. The bill also bars step therapy for the covered Alzheimer’s treatments and sets staggered effective dates, including a July 1, 2025 start for the State Employees Group Insurance Program and a January 1, 2027 applicability date for private and other covered plans.
The available record suggests generally positive sentiment toward the bill, with the measure framed as an access-to-care expansion for people with Alzheimer’s disease and related dementias. No committee transcripts or recorded votes were provided, so there is no documented opposition or floor debate in the supplied materials. The absence of recorded controversy indicates the bill was likely viewed as a health-benefit mandate with broad patient-support appeal.
No formal contention is documented in the provided transcripts or votes, but the bill’s likely pressure points are financial and administrative. Insurers, HMOs, and public employers may object to the cost of covering newer Alzheimer’s therapies and associated diagnostic testing, especially given the prohibition on step therapy. Another possible point of concern is the carve-out for managed care plans under contract with the Department of Healthcare and Family Services, which creates different treatment across coverage types and could raise questions about uniformity and implementation.